Silent cerebral infarcts following pulmonary vein isolation with different atrial fibrillation ablation techniques – incidence and risk factors

Andrzej Glowniak1, Adam Tarkowski1, Marzena Janczarek2, Andrzej Wysokinski1

1Department of Cardiology, Medical University of Lublin, Lublin, Poland
2Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Lublin, Poland

Submitted: 29 March 2019; Accepted: 30 April 2019
Online publication: 24 May 2019

Arch Med Sci 2022; 18 (3): 632–638
DOI: https://doi.org/10.5114/aoms.2019.85348
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Silent cerebral infarcts (SCIs) detected by diffusion-weighted magnetic resonance (DW-MRI) following atrial fibrillation (AF) ablation have been reported, with the incidence of 1–38%. We aimed to compare the incidence of SCIs following AF ablation with four different technologies and analyze the risk factors.

Material and methods: A total of 104 patients (mean age: 59.9 ± 9.5 years, 68 males) with symptomatic AF referred for ablation, were included in the study. The AF ablation was performed with irrigated radiofrequency point-by-point technique (RF group) in 24 patients, and with 3 different single-shot techniques: phased-RF (PVAC) in 46, second-generation cryoballoon (CB) in 24 and irrigated multipolar RF catheter (nMARQ) in 10 patients. In all patients DW-MRI was performed pre- and post-procedurally to evaluate the incidence of SCIs. Procedural parameters, complication rate and post-procedural SCI incidence were compared between the groups.

Results: Procedure (167.1 vs. 110.5 vs. 106.0 vs. 141.5 min, \( p < 0.001 \)), fluoroscopy (22.7 vs. 15.9 vs. 16.3 vs. 15.3 min, \( p = 0.048 \)) and LA dwell (101.5 vs. 53.9 vs. 56.0 vs. 97.0 min, \( p < 0.001 \)) times compared respectively between RF, PVAC, CB and nMARQ groups were significantly shorter with single-shot techniques. The number of new-onset SCIs was 4/24 (16.7%) in RF, 7/46 (15.2%) in PVAC, 1/24 (4.2%) in CB and 1/10 (10%) in the nMARQ group. Univariate analysis identified procedure duration (\( p = 0.02 \)), lower LV ejection fraction (\( p = 0.03 \)), persistent form of arrhythmia (\( p = 0.007 \)) and intraprocedural cardioversion (\( p = 0.002 \)) as risk factors of new-onset SCIs.

Conclusions: Silent cerebral infarcts can be detected following AF ablation regardless of the technology used. Prolonged procedure time, lower ejection fraction, persistent form of arrhythmia and intraprocedural cardioversion increase the risk of SCIs.

Key words: atrial fibrillation, cryoballoon, phased-radiofrequency ablation, pulmonary vein isolation, silent cerebral infarcts.

Introduction

Catheter ablation has become a standard therapeutic option in patients with symptomatic, drug-refractory atrial fibrillation (AF) [1–3]. Pulmonary vein isolation (PVI), confirmed with documented bidirectional conduction block between the left atrium (LA) and pulmonary veins (PVs),
Silent cerebral infarcts following pulmonary vein isolation with different atrial fibrillation ablation techniques – incidence and risk factors

is the cornerstone of AF ablation [4]. The conventional approach, i.e. circumferential isolation of ipsilateral PVs achieved point-by-point with an irrigated single-tip radiofrequency (RF) catheter (usually with the support of a three-dimensional electroanatomical system), is a time-consuming procedure. To facilitate the AF ablation procedure, several “single-shot” devices have been developed [5–8], leading to substantial shortening of the procedure time with a safety profile and long-term success rate comparable to classical point-by-point PVI [9–14]. Silent cerebral infarcts (SCIs), detected by diffusion-weighted magnetic resonance imaging (DW-MRI), associated with many types of cardiovascular interventions, have been widely described [15–18], but they are usually linked with PVI procedures [19–24] due to the specific target areas in the left atrium and higher initial risk of thromboembolic events in the AF population. In some of the single-shot techniques, the reported increased incidence of SCIs, detected with post-procedural DW-MRI, is of particular concern [21, 22].

In our study, we aimed to compare the incidence of SCIs detected with DW-MRI following AF ablation with four different technologies: classical point-by-point ablation with single-tip irrigated RF catheter and three different single-shot devices – non-irrigated multipolar phased-RF catheter, second-generation cryoballoon and multipolar irrigated RF catheter.

Material and methods

Study population

One hundred and four patients of mean age 59.9 ±9.5 years (68 males) with symptomatic AF, referred for ablation in our center, were included in the study. Exclusion criteria were previous AF ablation, enlarged (> 50 mm) left atrium (LA), left atrial thrombus, long-lasting persistent AF, substantial valvular heart disease, left ventricular (LV) ejection fraction ≤ 40%, heart failure (NYHA class III or IV), history of myocardial infarction or episode of unstable angina within the past 6 months, thyroid dysfunction, contraindication to oral anticoagulants, pregnancy and contraindication to magnetic resonance imaging. The distribution of factors potentially related to thromboembolic risk (comorbidities, LA diameter, persistent form of AF) was well balanced between the groups (Table I). Arterial hypertension was the most frequent co-morbidity in all groups, which is consistent with other observations regarding the AF population [23–27]. The ablation procedure was performed with irrigated radiofrequency point-by-point technique (RF group) in 24 patients, and with 3 different single-shot techniques: a non-irrigated duty-cycled phased-RF catheter (PVAC) in 46 patients, a second-generation cryoballoon (CB) in 24 patients and with an irrigated multipolar RF catheter (nMARQ) in 10 patients. The choice of the ablation technique was at the operator’s discretion. Most of the procedures (RF: 17/24 (71%), PVAC: 41/46 (89%), CB: 21/24 (88%), nMARQ: 8/10 (80%)) were performed by A.G., with no significant differences between the groups (p = 0.24).

In all patients DW-MRI was performed before and within 24 h after the ablation procedure to evaluate the incidence of SCIs. Procedural parameters, complication rate and post-procedural SCI incidence were compared between the groups. Patient characteristics are presented in Table I. The study protocol was approved by the institutional review board and written informed consent was signed by all patients.

Periprocedural management

A computed tomography (CT) scan or contrast venography was performed to evaluate pulmonary veins and LA anatomy. All patients were on oral anticoagulation prior to the procedure. For vitamin K antagonists (VKAs), an uninterrupted anticoagulation strategy was applied with therapeutic values of international normalized ratio (INR) [28]. For novel oral anticoagulants (NOACs), an interrupted regimen was accepted, with the preceding dose 12 to 24 h before, and the following dose 6 h after the ablation procedure. In all patients, transesophageal echocardiography (TEE) was performed before the procedure to exclude left atrial thrombus.

Ablation procedure

All procedures were performed under conscious sedation with local anesthesia. After two punctures in the right femoral vein (three punctures in the group of patients undergoing point-by-point ablation) a steerable quadrupolar diagnostic catheter was inserted into the coronary sinus (CS). Transseptal puncture was performed under fluoroscopic guidance using the 10-French (SL0, St. Jude Medical) sheath, which was continuously flushed with heparinized saline (1 U/ml) throughout the procedure. A loading dose (5000 IU) of heparin was given to all patients before the transseptal puncture. Immediately after crossing the septum, an additional weight-dependent dose of heparin was given to reach 70 IU/kg. The total dose was titrated based on activated clotting time (ACT) value (checked at 20-minute intervals) to maintain the ACT level above 300 s throughout the procedure.

In the RF group, the AF ablation procedure was performed using the 3D electroanatomical sys-
tem CARTO (Biosense Webster Inc, Diamond Bar, CA, USA) and a contact-force ablation catheter, SmartTouch (Biosense Webster Inc, Diamond Bar, CA, USA), in 15 patients; in 9 patients, a standard irrigated catheter was used (ThermoCool, Biosense Webster Inc, Diamond Bar, CA, USA). In all patients, a circular diagnostic catheter – Lasso (Biosense Webster Inc, Diamond Bar, CA, USA) – was used for 3D mapping of the left atrium. The Lasso catheter was introduced via the separate transseptal sheath in all patients to eliminate the need for catheter replacement during the procedure. The RF generator – EP Shuttle (Stockert GmbH, Freiburg, Germany) – was set at power control mode with maximum power of 35 W (limited to 25 W at posterior wall). In all patients, wide antral circumferential ablation was performed with both ipsilateral veins isolated together. In 12 (50%) patients, an additional substrate modification was performed: mitral isthmus and roof lines in 9 patients and in the cavo-tricuspid isthmus (CTI) line in 4 patients with a history of concomitant typical atrial flutter (1 patient had both LA and CTI lines performed together with PVI).

In the PVAC group, a circular multipolar catheter (PVAC, Medtronic, Minneapolis, USA) and dedicated multichannel duty-cycled phased-RF energy generator (GENius, Medtronic, Minneapolis, USA) were used, as described elsewhere [6, 7]. A modified PVAC Gold catheter was used in the last twelve cases. Phased-RF energy applications of 60 s were delivered with a unipolar/bipolar ratio of either 4 : 1 (8 W) or 2 : 1 (10 W), until pulmonary vein isolation was achieved.

In the CB group, all procedures were performed with a 28 mm second-generation cryoballoon (Arctic Front Advance, Medtronic, Minneapolis, MN, USA), as described elsewhere [5, 11]. All pulmonary veins were mapped with an inner lumen mapping catheter – Achieve 20 mm (Medtronic, Minneapolis, MN, USA). Vessel occlusion was considered optimal when selective contrast injection showed no backflow to the atrium. Once occlusion was documented; cryoapplication was commenced. In the first 8 patients double 4-minute freeze was applied. In all others, a single 3-minute freeze strategy was applied.

In the nMARQ group the ablation process was similar to the PVAC technique. The main difference was the use of a 3D electroanatomical system (CARTO, Biosense Webster Inc, Diamond Bar, CA, USA) in order to create a three-dimensional anatomical map of the left atrium and to confirm the positioning of the irrigated circular nMARQ catheter against the PV ostia. The power of unipolar RF application was set at 20 W (15 W at posterior wall) and maximum time of a single application was 30 s.

In all procedures performed with single-shot devices (PVAC, CB and nMARQ) pulmonary veins were the only target, with no additional substrate modification. In all patients, at the end of the procedure bidirectional PV isolation was confirmed with either a Lasso, PVAC, Achieve or nMARQ.

### Table I. Characteristics of the patients

| Parameter | RF group (n = 24) | PVAC group (n = 46) | CB group (n = 24) | nMARQ group (n = 10) | P-value |
|-----------|------------------|--------------------|------------------|----------------------|--------|
| Age [years]* | 58.0 ±9.15 | 60.7 ±8.8 | 59.7 ±10.3 | 61.4 ±12.1 | 0.49 |
| Male     | 17 (71%) | 34 (74%) | 19 (79%) | 8 (80%) | 0.89 |
| BMI [kg/m²]* | 28.6 ±2.4 | 27.5 ±2.6 | 26.8 ±6.0 | 27.6 ±2.3 | 0.42 |
| Heart failure | 1 (4.2%) | 1 (2.2%) | 0 (0%) | 1 (10%) | 0.43 |
| Hypertension | 18 (75%) | 32 (70%) | 18 (75%) | 8 (80%) | 0.89 |
| Diabetes | 4 (17%) | 10 (22%) | 6 (25%) | 2 (20%) | 0.91 |
| Previous stroke | 2 (8.3%) | 2 (4.3%) | 2 (8.3%) | 0 (0%) | 0.60 |
| CHA₂DS₂-VASc score* | 1.6 ±1.6 | 1.7 ±1.2 | 1.8 ±1.4 | 1.9 ±0.9 | 0.74 |
| LA diameter [mm]* | 43.0 ±4.6 | 42.8 ±3.3 | 42.5 ±2.6 | 43.7 ±2.8 | 0.48 |
| LV ejection fraction (%)* | 62.9 ±5.0 | 60.3 ±4.7 | 63.2 ±5.2 | 60.2 ±5.2 | 0.07 |
| Persistent AF | 3 (13%) | 3 (7%) | 2 (8%) | 1 (10%) | 0.87 |

*Data presented as mean ± SD; BMI – body mass index, LA – left atrium, LV – left ventricle, AF – atrial fibrillation.
catheter. The choice of the AF ablation technique was at the operator’s discretion. In all cases, the procedure time, fluoroscopy time and the duration of the catheters’ dwell in the left atrium (LA dwell time) were recorded. Transthoracic echocardiogram was performed after the procedure to exclude pericardial effusion in all patients.

**Diffusion-weighted MRI**

Magnetic resonance imaging (1.5 Tesla Siemens Avanto) was performed the day before and 24–48 h after the ablation procedure in all patients, as described before [18]. Acute ischemic lesions were defined as focal diffusion anomalies – “bright signals”. Additionally, the apparent diffusion coefficient (ADC) was measured to support image analysis in equivocal cases. All MRI scans were analyzed by a certified radiologist.

**Statistical analysis**

Statistical analysis was carried out using appropriate statistical tests and Statistica 13.3, TIBCO Software Inc. (StatSoft, USA). The values of the parameters were presented as arithmetic means and their standard deviations (SD), medians, minimum and maximum value, and the range of variability. Normal distribution of continuous variables was tested using the Shapiro-Wilk test. The Student t-test or Mann-Whitney U-test was used for intergroup comparisons. The distribution of discrete variables in groups was compared using Pearson’s χ² test or Fisher’s exact test. Logistic regression models were fitted to identify risk factors associated with the occurrence of SCI. From these models, adjusted odds ratios (OR) and 95% confidence intervals were derived; corresponding p-values were those from Wald’s test. Goodness of fit was checked using Hosmer and Lemeshow’s test. The error was set at 5% and significance at p-value < 0.05.

**Results**

**Procedural parameters and complications**

Procedure (167.1 vs. 110.5 vs. 106.0 vs. 141.5 min, p < 0.001), LA dwell (101.5 vs. 53.9 vs. 56.0 vs. 97.0 min, p < 0.001) and fluoroscopy (22.7 vs. 15.9 vs. 16.3 vs. 15.3 min, p = 0.048) times differed significantly within the RF, PVAC, CB and nMARQ groups, respectively. When compared to classical RF point-by-point PVI, all three single-shot techniques had significantly shorter procedure time: RF vs. PVAC (p < 0.001), RF vs. CB (p < 0.001) and RF vs. nMARQ (p = 0.027). The LA dwell time was significantly shorter in PVAC (p < 0.001) and CB (p < 0.001) groups, but not in the nMARQ group (p = 0.59). Similarly, the fluoroscopy time was significantly reduced with PVAC (p < 0.001) and CB (p = 0.026), and slightly shorter in the nMARQ group (p = 0.076).

There were no major complications of the ablation procedure. Minor complications occurred in 9 (8.6%) patients and involved local groin hematoma in 8 patients and one pseudoaneurysm of the right femoral artery, which was effectively treated with ultrasound-guided compression. There was no significant difference in complication rate between the groups (p = 0.87). The summary of procedural parameters and complications is presented in Table I.

**Incidence of silent cerebral infarcts following the ablation procedure**

New-onset SCIs detected by post-procedural DW-MRI occurred in 4 (16.7%) patients in the RF group, 7 (15.2%) patients in the PVAC group, and in 1 patient both in CB (4.2%) and nMARQ (10%) groups (Figure 1). All of the revealed infarcts were clinically silent and there were no neurological symptoms following the procedure. In a univariable analysis the need for intraprocedural cardioversion (p = 0.002), persistent form of arrhythmia (p = 0.007), procedure time (p = 0.02), and lower LV ejection fraction (p = 0.03) were identified as risk factors of new-onset SCIs (Table II).

**Discussion**

**Procedural parameters and complications**

Single-shot devices dedicated for AF ablation were developed to simplify PVI and reduce the procedure time. We demonstrated significantly shorter procedural duration, LA dwell and fluoroscopy times with two single-shot techniques – phased RF multipolar catheter (PVAC) and second-generation cryoballoon – compared to classical point-by-point RF. For the irrigated multipolar RF catheter (nMARQ) only reduction of the procedure duration was demonstrated, without a significant change in fluoroscopy and LA dwell time. There are two possible explanations for this difference. First, our results regarding a significant reduction of procedure time with PVAC and CB are in line with previous reports [9–13]. Second, the nMARQ group included the first 10 patients ablated with this technique in our center, and thus the operator’s caution with the new technology can explain the relatively longer procedure duration. Interestingly, in a recently published report comparing PVAC and nMARQ catheters, both the procedure and fluoroscopy times were significantly shorter with the latter technique [12].

The observed rate of minor complications did not differ between the groups and was comparable with previously reported rates [5–14]. This is an
important remark, since the main reason for development of single-shot technologies was to simplify the procedure without compromising its safety.

Incidence of silent cerebral infarcts following the ablation procedure

In our study, we compared the incidence of silent cerebral infarcts detected by DW-MRI following AF ablation performed with four different technologies.

This phenomenon, associated with cardiovascular interventions, was described predominantly following catheter ablation procedures [18–24]. The clinical significance of SCIs, by definition asymptomatic, is being discussed, and there are data linking this phenomenon with dementia and gradual cognitive decline [29, 30]. Furthermore, SCIs can be considered as a marker of thrombogenicity of cardiovascular interventions. Fortunately, clinically apparent stroke does not happen frequently enough during most cardiovascular procedures to help us to analyze its risk factors, except in very large cohorts. In our opinion, expressed before [18], SCIs can serve as a “substitute” of stroke, permitting the search for potential risk factors.

Table II. Univariable analysis of SCI incidence risk factors

| Parameter                      | SCI (–) (n = 91) | SCI (+) (n = 13) | OR (95% CI) | P-value |
|--------------------------------|------------------|-----------------|-------------|---------|
| Age [years]*                  | 60.2 ±9.8        | 57.8 ±6.8       | 0.97 (0.9–1.03) | 0.16 |
| Male                          | 66 (73%)         | 12 (92%)        | 4.5 (0.6–36.8) | 0.77 |
| BMI [kg/m²]*                  | 27.6 ±3.7        | 27.3 ±2.6       | 0.98 (0.8–1.1) | 0.43 |
| CHA₂DS₂-VASC score*          | 1.77 ±1.4        | 1.46 ±0.97      | 0.82 (0.5–1.3) | 0.03 |
| LA diameter [mm]*             | 42.8 ±3.5        | 43.4 ±3.1       | 1.05 (0.9–1.3) | 0.77 |
| LV ejection fraction (%)*     | 62.0 ±5.0        | 58.5 ±4.9       | 1.05 (0.8–1.0) | 0.57 |
| Left common PV trunk          | 15 (17%)         | 3 (23%)         | 1.5 (0.4–6.1) | 0.57 |
| Persistent AF                 | 5 (6%)           | 4 (31%)         | 2.8 (1.3–5.8) | 0.007 |
| CRP [mg/l]*                   | 2.2 ±4.5         | 2.7 ±5.7        | 1.0 (0.9–1.1) | 0.71 |
| BNP [pg/ml]*                  | 73.7 ±67.0       | 55.9 ±53.0      | 0.99 (0.98–1.0) | 0.36 |
| Urea [mg/dl]*                 | 39.1 ±9.0        | 43.2 ±8.7       | 1.05 (1.0–1.1) | 0.13 |
| Creatinine [mg/dl]*           | 0.95 ±0.2        | 0.98 ±0.23      | 2.2 (0.2–32.3) | 0.56 |
| eGFR [ml/min]*                | 82.6 ±15.7       | 81.3 ±15.23     | 0.99 (0.9–1.03) | 0.77 |
| Procedure time [min]*         | 122.3 ±31.9      | 147.7 ±39.3     | 1.02 (1.0–1.0) | 0.02 |
| LA dwell time [min]*          | 68.3 ±24.5       | 77.8 ±32.8      | 1.0 (0.99–1.03) | 0.22 |
| DC cardioversion              | 9 (10%)          | 6 (46%)         | 7.7 (2.1–28.0) | 0.002 |
| ACT during procedure*         | 354.0 ±51.0      | 332.9 ±43.7     | 0.99 (0.98–1.0) | 0.16 |

*Data presented as mean ± SD; SCI – silent cerebral infarcts, OR – odds ratio, CI – confidence interval, BMI – body mass index, LA – left atrium, LV – left ventricle, PV – pulmonary vein, AF – atrial fibrillation, CRP – C-reactive protein, BNP – brain natriuretic peptide, eGFR – estimated glomerular filtration rate, DC – direct current, ACT – activated clotting time.

Figure 1. DW-MRI before (A) and after (B) the ablation procedure, demonstrating new ischemic lesion in the left temporal lobe.
One of the techniques (nMARQ), which may con-
and the operators had much less experience with
formed on a relatively small number of patients,
no longer detectable in DW-MRI performed sever-
majority of cases the post-procedural SCIs were
this phenomenon is clinically relevant, since in the
LV ejection fraction as a risk factor of periproce-
by a preexisting prothrombotic state in patients
fraction and the new-onset SCIs can be explained
mia [32] and electrical cardioversion [20] during
relations between SCIs and the type of arrhyth-
ful influence on the risk of silent cerebral infarcts. The
prolonged procedure time might itself have an in-
dent predictors of SCI occurrence (Table II). The
incidence, though probably not on the procedural
procedure duration, lower LV ejection fraction,
persistent form of arrhythmia and the need for an
procedure time, lower LV ejection fraction, per-
sistent form of arrhythmia and a need for intra-
rocedural cardioversion increase the risk of silent
silent cerebral infarcts following the ablation procedure.

**Conflict of interest**
Andrzej Glowniak has received compensation for proctoring and speaking duties from Medtron-
ic and for speaking duties from Abbott. Other au-
thors declare no conflict of interest.

**References**
1. Kirchhof P, Benussi D, Kotecha A, et al. 2016 ESC guide-
lines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-78.
2. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/ EHRA/ECAS/APHRS/SOLAECE expert consensus state-
mion on catheter and surgical ablation of atrial fibrilla-
ation. Europace 2018; 20: e1-160.
3. Kawaji T, Shizuta S, Morimoto T, et al. Very long-term clinical outcomes after radiofrequency catheter ablation for atrial fibrillation: a large single-center experience. Int J Cardiol 2017; 249: 204-13.
4. Verma A, Jiang CY, Betts TR, et al.; STAR AF II Investi-
gators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015; 372: 1812-22.
5. Van Belle Y, Janse P, Rivero-Ayerza MJ, et al. Pulmonary vein isolation by duty-cycled bipolar and unipolar radiofrequency energy. J Cardiovasc Electrophysiol 2010; 33: 168-78.
6. Boersma LV, Wijffels MC, Oral H, Wever EF, Morady F. Pulmonary vein isolation by duty-cycled bipolar and unipolar radiofrequency energy with a multielectrode ablation catheter. Heart Rhythm 2008; 5: 1635-42.
7. Scharf C, Boersma L, Davies W, et al. Ablation of persist-
tent atrial fibrillation using multielectrode catheters and duty-cycled radiofrequency energy. J Cardiovasc Electrophysiol 2010; 21: 399-405.
8. Duytschaever M, Anne W, Papiashvili G, Vandeckr-
hove Y, Tavernier R. Mapping and isolation of the pul-
monary veins using the PVAC catheter. Pacing Clin Electrophysiol 2010; 33: 168-78.
9. Gal P, Aarnizt AE, Smit JJ, et al. Conventional radiofre-
cuency catheter ablation compared to multi-electrode ablation for atrial fibrillation. Int J Cardiol 2014; 176: 891-5.
10. McCready J, Chow AW, Lowe MD, et al. Safety and effi-
cacy of multipolar pulmonary vein ablation catheter vs. irri-
gated radiofrequency ablation for paroxysmal atrial
fibrillation: a randomized multicenter trial. Europace 2014; 16: 1145-53.
11. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016; 374: 2235-45.
12. Koźluk F, Piątkowska A, Rodkiewicz D, Peller M, Kočanowski J, Opolski G. Direct results of a prospective randomized study comparing catheterization with the nMARQ catheter and the PVAC catheter used with and without a 3D system (MAPER 3D Study). Arch Med Sci 2019; 15: 78-85.
13. Chen CE, Gao XF, Duan X, Chen B, Liu XH, Xu YZ. Comparison of catheter ablation for paroxysmal atrial fibrillation between cryoballoon and radiofrequency: a meta-analysis. J Interv Card Electrophysiol 2017; 48: 351-66.
14. Glowniak A, Tarkowski A, Fic P, Wojewoda K, Wojcik J, Wysokinski A. Second-generation cryoballoon ablation for recurrent atrial fibrillation after an index procedure with radiofrequency versus cryo: different pulmonary vein reconnection patterns but similar long-term outcome – results of a multicenter analysis. J Cardiovascular Electrophysiology 2019; doi: 10.1111/jce.13938.
15. Büssing KA, Schulte-Sasse C, Flüchter S, et al. Cerebral Infarction: Incidence and risk factors after diagnostic and interventional cardiac catheterization – prospective evaluation at diffusion-weighted MR imaging. Radiology 2005; 235: 177-83.
16. Barth A, Remonda L, Lövblad KO, Schroth G, Seiler RW. Silent cerebral ischemia detected by diffusion-weighted MRI after carotid endarterectomy. Stroke 2000; 31: 1824-8.
17. Rodés-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism following transcatheter aortic valve implantation. J Am Coll Cardiol 2011; 51: 18-28.
18. Glowniak A, Janczarek M, Tarkowski A, et al. Silent cerebral infarcts following left-sided accessory pathway ablation in Wolff-Parkinson-White syndrome: a preliminary report. Med Sci Monit 2019; 25: 1336-41.
19. Lickfett L, Hackenbroch M, Lewalter T, et al. Cerebral diffusion-weighted magnetic resonance imaging: a tool to monitor the thrombogenicity of left atrial catheter ablation. J Cardiovascular Electrophysiology 2006; 17: 1-7.
20. Gaita F, Caponi D, Planelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122: 1667-73.
21. Herrera-Siklódy C, Deneke T, Hocini M, et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol 2011; 58: 681-8.
22. Gaita F, Leclercq JF, Schumacher B, et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar non-irrigated catheter and cryoballoon. J Cardiovascular Electrophysiology 2011; 22: 961-9.
23. Verma A, Debruyne P, Nardi S, et al. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the ERACE trial. Circ Arrhythm Electrophysiol 2013; 6: 835-42.
24. Keçė E, Bruggemann E, de Riva M, et al. Incidence and clinical significance of cerebral embolism during atrial fibrillation ablation with duty-cycled phased-radiofrequency versus cooled-radiofrequency: a randomized controlled trial. JACC Electrophysiol 2019; 5: 318-26.
25. Zhang X, Li H, Kou W, et al. Increased plasma microfibrillar-associated protein 4 is associated with atrial fibrillation and more advanced left atrial remodelling. Arch Med Sci 2018; 15: 632-40.
26. Koteleva D, Goląb-Janowska M, Meller A, et al. Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. Arch Med Sci 2019; 15: 385-92.
27. Demir G, Güneş H, Seker M, et al. Is the presence of left atrial diverticulum associated with recurrence in patients undergoing catheter ablation for atrial fibrillation? Arch Med Sci Atheroscler Dis 2019; 4: 25-31.
28. Di Biase L, Burkhart JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-6.
29. De Groot JC, De Leeuw FE, Oudkerk M, et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002; 52: 335-41.
30. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-22.
31. Martinek M, Sigmund E, Lemes C, et al. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation. Europace 2013; 15: 325-31.
32. Di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 2014; 11: 791-8.
33. Sakamoto T, Kumagai K, Nishiuchi S, et al. Predictors of asymptomatic cerebral infarction associated with radiofrequency catheter ablation for atrial fibrillation using an irrigated-tip catheter. Europace 2012; 15: 332-8.
34. Schmidt B, Gunawardene M, Krieg D, et al. A prospective randomized single-center study on the risk of asymptomatic cerebral lesions comparing irrigated-tip radiofrequency catheter ablation for atrial fibrillation using the cryoballoon and the laser balloon. J Cardiovasc Electrophysiology 2013; 24: 869-74.
35. Schrickel JW, Lickfett L, Lewalter T, et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2009; 12: 52-7.
36. Chong AV, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail 2007; 9: 124-8.
37. Deneke T, Shin DI, Balta O, et al. Postablation asymptomatic cerebral lesions: long-term follow-up using magnetic resonance imaging. Heart Rhythm 2011; 8: 1705-11.